<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Collection:</title>
  <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46276" />
  <subtitle />
  <id>http://dspace.bsuedu.ru/handle/123456789/46276</id>
  <updated>2026-04-07T18:41:57Z</updated>
  <dc:date>2026-04-07T18:41:57Z</dc:date>
  <entry>
    <title>Preclinical study of innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46629" />
    <author>
      <name>Golubev, I. V.</name>
    </author>
    <author>
      <name>Gureev, V. V.</name>
    </author>
    <author>
      <name>Korokin, M. V.</name>
    </author>
    <author>
      <name>Serdyuk, E. A.</name>
    </author>
    <author>
      <name>Soldatova, V. A.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46629</id>
    <updated>2022-05-06T00:16:40Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: Preclinical study of innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin
Authors: Golubev, I. V.; Gureev, V. V.; Korokin, M. V.; Serdyuk, E. A.; Soldatova, V. A.
Abstract: The aim of this study was to examine the effectiveness of innovative peptides obtained by addition of polypeptide motifs with antiaggregation activity (Arg-Gly-Asp, Lys-Gly-Asp and Pro-Gly-Pro) to a peptide mimicking the tertiary structure of the α-helix B of erythropoietin pHBSP (Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser)</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Medication adherence in patients with stable coronary artery disease in primary care</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46586" />
    <author>
      <name>Zyryanov, S. K.</name>
    </author>
    <author>
      <name>Fitilev, S. B.</name>
    </author>
    <author>
      <name>Vozzhaev, A. V.</name>
    </author>
    <author>
      <name>Shkrebniova, I. I.</name>
    </author>
    <author>
      <name>Shindryaeva, N. N.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46586</id>
    <updated>2022-05-05T00:22:01Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: Medication adherence in patients with stable coronary artery disease in primary care
Authors: Zyryanov, S. K.; Fitilev, S. B.; Vozzhaev, A. V.; Shkrebniova, I. I.; Shindryaeva, N. N.
Abstract: Medication non-adherence in coronary outpatients exceeded 50%. High adherence was associated with more frequent use of fixed dose combinations and fewer pills taken by patient</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>On the way from SARS-CoV-sensitive mice to murine COVID-19 model</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46585" />
    <author>
      <name>Soldatov, V. O.</name>
    </author>
    <author>
      <name>Kubekina, M. V.</name>
    </author>
    <author>
      <name>Silaeva, Yu. Yu.</name>
    </author>
    <author>
      <name>Bruter, A. V.</name>
    </author>
    <author>
      <name>Deykin, A. V.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46585</id>
    <updated>2022-05-05T00:16:09Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: On the way from SARS-CoV-sensitive mice to murine COVID-19 model
Authors: Soldatov, V. O.; Kubekina, M. V.; Silaeva, Yu. Yu.; Bruter, A. V.; Deykin, A. V.
Abstract: The coronavirus disease 2019 (COVID-19) is a master killer which appeared suddenly and which has already claimed more than 200,000 human lives. In this situation, laboratories are in urgent need for a COVID-19 murine model to search for effective antiviral compounds</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Molecular docking, ADMET study and in vivo pharmacological research of N-(3,4-dimetoxyphenyl)-2-{[2-methyl-6-(pyridine-2-yl)-pyrimidin-4-yl]thio}acetamide as a promising anticonvulsant</title>
    <link rel="alternate" href="http://dspace.bsuedu.ru/handle/123456789/46584" />
    <author>
      <name>Severina, H. I.</name>
    </author>
    <author>
      <name>Skupa, O. O.</name>
    </author>
    <author>
      <name>Voloshchuk, N. I.</name>
    </author>
    <author>
      <name>Saidov, N.</name>
    </author>
    <author>
      <name>Bunyatyan, V. A.</name>
    </author>
    <id>http://dspace.bsuedu.ru/handle/123456789/46584</id>
    <updated>2022-05-05T00:13:46Z</updated>
    <published>2020-01-01T00:00:00Z</published>
    <summary type="text">Title: Molecular docking, ADMET study and in vivo pharmacological research of N-(3,4-dimetoxyphenyl)-2-{[2-methyl-6-(pyridine-2-yl)-pyrimidin-4-yl]thio}acetamide as a promising anticonvulsant
Authors: Severina, H. I.; Skupa, O. O.; Voloshchuk, N. I.; Saidov, N.; Bunyatyan, V. A.
Abstract: The search for new anticonvulsants for epilepsy treatment with higher efficacy and better tolerability remains important. The aim of the present research was an in silico and in vivo pharmacological study of N-(3,4-dimethoxyphenyl)-2-((2-methyl-6-(pyridin-2-yl)pyrimidin-4-yl)thio)acetamide (Epirimil) as a promising anticonvulsant</summary>
    <dc:date>2020-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

